A study using a mouse solid tumour model suggests that adjusting the dosing frequency of the PI3Kδ inhibitor AMG319 in the treatment of human cancers could decrease tumour growth with fewer adverse effects.
- Simon Eschweiler
- Ciro Ramírez-Suástegui
- Christian H. Ottensmeier